Paragon nabs $15M filovirus vax contract from DoD

The U.S. Department of Defense has awarded Paragon Bioservices, a contract manufacturing organization, a $15 million contract to develop a mammalian process to manufacture vaccines for filoviruses, which are considered potential bioweapons.  Paragon also has been working on vaccines that would guard against the Ebola and related Marburg viruses. Story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.